Comparing the effectiveness of treating branch retinal vein occlusion with a novel One and Stepped Pro Re Nata treatment protocol

Comparing the effectiveness of treating branch retinal vein occlusion with a novel One and Stepped Pro Re Nata treatment protocol | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Comparing the effectiveness of treating branch retinal vein occlusion with a novel One and Stepped Pro Re Nata treatment protocol Po-Yu(Jay) Chen, Alan Y. Hsu, Chun-Ting Lai, Chun-Ju Lin, Ning-Yi Hsia, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4478566/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 14 Aug, 2025 Read the published version in Medicine → Version 1 posted You are reading this latest preprint version Abstract This study aimed to investigate the anatomical and functional outcomes of branch vein occlusion (BRVO) eyes treated with anti-VEGF injections using a novel One and Stepped pro re nata (PRN) protocol. This retrospective case series evaluated the electronic medical records from 22 BRVO patients who were treated with anti-VEGF agents under our novel “One and Stepped PRN” protocol at a single tertiary medical center between January 2016 and October 2022. Outcomes of interest included best-corrected visual acuity and central retinal thickness. 22 treatment-naive BRVO eyes (14 males, eight females) were included. The mean age was 65.82+/- 10.88 years. Average follow-up was 54.45 +/- 7.65 weeks. 7 (31.81%) received mainly Ranibizumab, and 15 (68.18%) received mainly Aflibercept. The baseline average BCVA was 45.86 +/- 19.46 ETDRS letters, and the baseline average CRT was 562.5 +/- 164.02 µm. The mean number of injections received was 3.54 +/- 1.74. Average BCVA improvement was 23.91 +/- 17.36 ETDRS letters (p < 0.0001) and average CRT improvement was 245.55 +/- 153.31 µm (p < 0.0001). Our results were comparable to the BRAVO and VIBRANT trials while comparatively using fewer anti-VEGF injections. In summary, our novel anti-VEGF protocol applied under real-world conditions achieved good anatomical and visual outcomes among treatment-naive BRVO eyes. Health sciences/Health care/Therapeutics/Drug therapy Health sciences/Diseases/Eye diseases/Retinal diseases Anti-VEGF anti-vascular endothelial growth factor BRVO branch retinal vein occlusion IVI intra-vitreal injection Figures Figure 1 Introduction Branch retinal vein occlusion (BRVO) is the occlusion of the retinal veins branches due to mechanical compression, vessel wall degeneration, or hypercoagulative status[ 1 , 2 ]. One of the leading causes of reduction in visual acuity among BRVO patients is macular edema (ME) [ 3 ]. The other complications of BRVO can include neovascular development. This can result in vitreous haemorrhage, tractional retinal detachment, or neovascular glaucoma. Intravitreal injection(IVI) of Anti-vascular endothelial growth factor (anti-VEGF) therapies become the mainstay treatment to manage BRVO eyes after being approved by the Food and Drug Administration (FDA) of the United States between 2010 and 2014[ 4 , 5 ]. Several trials have supported the clinical utility of anti-VEGF for BRVO patients. This includes the BRAVO study(monthly injection for 6 months and received injection if needed during month 6–11), the BRIGHTER study(In the Ranibizumab monotherapy arm, at least three monthly injections was given until vision was stable. The next retreatment will started only when vision decreased due to disease activity during monthly exam.), and the VIBRANT study (In the IVI group, injections were given every 4 weeks until week 24 and then every 8 weeks until week 48 with rescue grid laser if needed at week 36.) [ 6 – 8 ]. Most of the protocols of these studies started with a 3–6 monthly injection as loading phase regardless of edema condition, then proceeded with different follow up protocols. Despite their clear benefits, frequent anti-VEGF therapies may constitute a burden, including a financial burden and the risk of infection, for both patients and clinicians alike. In order to adjust to real world burden, protocols like Treat & Extend and PRN developed from treating age-related macular degeneration (AMD) and diabetic macular edema(DME) were applied to treat BRVO[ 9 , 10 ]. However, studies have reported that BRVO patients received no treatment could still achieve good outcomes [ 11 , 12 ]. This was described in a review that reported improvement in the visual acuity [ 12 ] among those with untreated BRVO eyes [ 13 ]. Such clinical results obtained from untreated BRVO eyes have been hypothesized to be due to the formation of collateral circulation as an adaption to bypass the total capillary bed obstruction seen among BRVO eyes [ 14 ]. Such collaterals can salvage residual retina function as well as decrease the occurrence of edema. This indicates a good prognosis from the perspective of pathophysiology and hemodynamics of BRVO. Under the finding that certain portions of patients under natural clinical course with good outcomes combined with the evidence of the collateral vessel maturation which is different from AMD and DME, this raise the question of whether we truly need that many injections of IVI-antiVEGF and whether these patients really require monthly follow-up. Unfortunately, available evidence on the different PRN protocols for BRVO eyes has been limited by their variability in study designs and protocols. For example, there was a lack of consensus on the use of a loading dose[ 15 ] as well as the clinical indications for IVI usage[ 16 ]. Also, none of these studies assessed the outcomes of extending the follow-up period instead of monthly intervals. This study aimed to assess the anatomical and functional outcomes of BRVO eyes with ME treated with our novel “One and Stepped PRN” anti-VEGF IVI protocol. We also sought to compare the efficacy of our novel PRN protocol with results from the BRAVO and VIBRANT trials. Material and Methods 2.1 Study population This retrospective and single institutional study involved the evaluation of electronic medical records of treatment naïve BRVO patients undergoing our proposed “One and Stepped PRN” anti-VEGF protocol. All patients underwent a routine ophthalmic examination at every visit. This included best-corrected visual acuity (BCVA) assessment and evaluation by spectral-domain optical coherence tomography (SD-OCT; Heidelberg Engineering, Heidelberg, Germany). The study period was from January 2016 to October 2022. This study has been approved by the Medical Center Research Ethics Committee from the China Medical University Hospital (CMUH112-REC1-044). It has been conducted in accordance with the principles of the Declaration of Helsinki. Due to the use of anonymized data obtained during routine clinical care, the informed consent was waived by the Ethics Committee’s approval. The inclusion criteria included patients of all ages diagnosed with BRVO and followed up for at least a year between January 2016 and October 2022. Furthermore, we only recruited patients with BRVO who received at least one dose of anti-VEGF within the study period. The exclusion criteria included patients with a history of other ocular diseases, including retina diseases (e.g., diabetic retinopathy and age-related macular degeneration). We also excluded those with a previous history of any anti-VEGF IVI therapies. However, if cataracts developed during the follow-up period, we only excluded them if the patient did not receive cataract surgery before the end of the follow-up time. Also, we only excluded patients with epiretinal membrane located within the parafovea (central 2.5mm in diameter). 2.2 Treatment Regime Our proposed “One and Stepped PRN” protocol for BRVO patients consisted of two phases: 1) a monthly treatment phase and 2) a stepped PRN phase. BRVO patients found to have ME will receive IVI of anti-VEGF during monthly follow up until the edema was resolved. When the ME has been resolved, the patient will be shifted to the stepped PRN phase of the protocol. As part of this modified PRN phase of the protocol, patients will initially return one month after the last IVI injection. This is followed by two months, then three months, until the maximum of 4 months after the initial date was reached (see Supplementary Fig. 1 ). Unlike treat and extend protocol, IVI was not given during all of these follow up time. However, if there was a re-occurrence of ME, monthly treatment of IVI anti-VEGF will be reinitiated until another resolution of ME is achieved one month after the last injection. The next follow-up period would be the longest interval the patient has had previously. ME for our study was defined as choroidal retinal thickness (CRT) greater than 300µm assessed by OCT or the presence of other evidence of intraretinal fluid (IRF) or subretinal fluid(SRF). To analyze the effects of different anti-VEGF IVI therapies, we classified our patients into three groups based on their treatment. Group 1 was composed of BRVO patients who only received Bevacizumab (Avastin) injections. Group 2 are patients who either received Ranibizumab (Lucentis) only or received Bevacizumab first and then Ranibizumab. Regarding Group 3, we classified patients who either received Aflibercept (Eylea) only or received Bevacizumab first and then Aflibercept. The reimbursement policy of the Taiwan National Health Insurance towards anti-VEGF IVI usage influenced the organization of our three treatment subgroups. To qualify for anti-VEGF IVI reimbursements, patients must first undergo review by the Taiwan National Health Insurance[ 17 ]. Therefore, Taiwanese patients often opt to self-pay for Bevacizumab treatment during this review period as a cost containment option [ 12 ]. 2.3 Outcome Measures The primary outcome of interest was the mean change from baseline BCVA recorded via Early Treatment Diabetic Retinopathy Study (ETDRS) letters and CRT changes assessed by OCT. In terms of baseline demographics, we collected factors such as age, certain medical comorbidities such as hypertension (HTN) and diabetes mellitus (DM) status, initial best-corrected distance visual acuity (BCVA), and central retina thickness (CRT). Other variables of interest included the total number of IVIs received, the final BCVA, and CRT. 3. Statistical analysis BCVA changes and CRT changes were calculated and compared by paired t-test. Sub-group analyses were classified based on the type of IVI and the presence of DM and HTN. Continuous variables were displayed by means and standard deviations (SD). Categorical variables were displayed by portion and percentage. The Kaplan-Meier plot displayed the incidence of recurrence. Results from our study were compared with previous trials (BRAVO [ 6 ] and VIBRANT[ 8 ]). Student’s t-test with unequal variance was conducted for continuous data and chi-square test and Fisher's exact test for categorical data. Regression analyses were performed to evaluate the potential risk factors. All statistical analyses were two-tailed, and statistically significant results were considered when the p-value was less than 0.05. STATA 1.4.2 was used for statistical analysis. Results 4.1 Baseline Data The demographic data is shown in Table 1 . 22 treatment naïve BRVO eyes (36.3% female; average age 65.82 +/- 10.8 years) were recruited for this study. Regarding anti-VEGF IVI therapies, none of our patients received Bevacizumab (Group 1) only. Seven patients received Ranibizumab as their primary treatment (and were listed under Group 2). Fifteen patients received Aflibercept as their primary treatment (and were listed under Group 3). The average follow-up duration was 54.45 +/- 7.65 weeks. 9 (40.9%) of our patients had DM, and 11 (50%) had HTN at baseline. The average BCVA at baseline was 45.86 ± 19.46 ETDRS letters, and the average initial CRT at baseline was 526.5 ± 164.02 μm. 4.2 Treatment effects Among our 22 patients recruited for this study, 7 received Ranibizumab (Group 2) as part of their anti-VEGF therapy, and 15 received Aflibercept (Group 3) as part of their anti-VEGF therapy. None of our patients received Bevacizumab only (Group 1) (see Table 2 ). No significant statistical difference was found between the patients from Group 2 and Group 3 in terms of initial BCVA (p=0.12), initial CRT (p=0.93), and the improvement of BCVA (p=0.93) and CRT (p=0.27) (see Table 2 ). The average injections of anti-VEGF given were 3.54 ± 1.74 (2±0.87 in the first three months) (see Table 1 ). The overall average BCVA improvement was 23.91 ± 17.36 ETDRS letters (p<0.0001), and the overall average CRT improvement was 245.55 ± 153.31 μm (p<0.0001) (see Table 1 ). Figure 1 shows the Kaplan-Meier survival curve (see Fig. 1 ) for all eyes recruited. Our Kaplan-Meier curve revealed a median of 12 weeks of stable condition without ME after the first resolution. Patients receiving PSTA had baseline BCVA that was worse than those who didn’t receive PSTA (31.38±6.26 vs. 54.14±4.14, p=0.005). However, initial CRT (p=0.41), BCVA improvement (p=0.80) and CRT improvement (p=0.69) did not significantly differ between these two groups. 4.3 Multivariable regression analysis Multivariable regression analysis was also performed to determine what factors may influence the improvement of final BCVA and CRT parameters compared to the baseline. We found that the initial baseline BCVA was a statistically significant negative predictor for improvement in BCVA at the final follow-up (p=0.030). In other words, patients with worse baseline BCVA reported more improvement in BCVA at follow-up. We also found that the initial CRT was a statistically significant predictor for improvement in CRT at the final follow-up (p<0.001). In other words, patients with higher baseline CRT reported more improvements in terms of CRT at the final follow-up (see Table 3 ). The factors of age, time from symptoms onset, and associated medical comorbidities of DM and HTN were found to have no significant effect on the overall BCVA and CRT improvement from baseline. 4.4 Statistical comparisons with other trials Several clinical parameters were compared between our results and the two previously published anti-VEGF-related trials (the BRAVO and VIBRANT study). The compared parameters included the average amount of IVI used, average initial and improvement in BCVA, and average initial and improvement in CRT. Compared to the BRAVO study[6], the number of anti-VEGF injections used within the first year from our Group 2 (Ranibizumab) participants was significantly lower in number (8.4 vs. 3.86±1.95, no SD in BRAVO for p-value calculation). In terms of other parameters of interest, there was no significant difference in initial BCVA between the BRAVO study and our group 2 participants (53.0±12.5 vs. 55.43±20.92, p=0.77), initial CRT (551.7±223.5 vs. 548.29±231.64, p=0.97), BCVA improvement (18.3±14.89 vs. 18.43±16.95, p=0.98) and CRT improvement (347.4 vs. 262.43, no SD in BRAVO for p-value calculation) (see Table 4 ). Compared to the VIBRANT 52 weeks study [8], the number of anti-VEGF injections received was significantly more than our Group 3 (Aflibercept) participants (9.0±1.8 vs. 3.73±1.58, p<0.0001). Regarding the proportion of patients with different degree of vision gain or vision loss, we found no significant difference between VIBRANT and our Group 3 (p=0.223) (see Table 5 and Table 6 ). Regarding other parameters of interest (e.g., initial BCVA and CRT), there was insufficient baseline data from the VIBRANT trial to calculate any statistical comparisons. Discussion This was a novel retrospective case series to investigate the effects of our novel “One and Stepped PRN” anti-VEGF protocol over naïve BRVO eyes. 5.1 Novel findings We found that the One and Stepped PRN anti-VEGF protocol significantly improved average BCVA and average CRT. The results also revealed a median stable condition in terms of no ME after the first resolution after 12 weeks. Furthermore, anatomical and functional parameters assessed within our study did not significantly differ among the different anti-VEGF agents used (i.e., Bevacizumab, Ranibizumab, and Aflibercept). Our multivariable regression analysis also revealed that initial BCVA and initial CRT have significantly affected final BCVA and CRT improvements, respectively. In terms of PSTA, this was designed as an adjuvant therapy for those with a relatively worse initial condition. This could be seen from our results, as the PSTA group reported worse initial BCVA but had similar gains in improvements (BCVA and CRT) at final follow-up. This indicated that such patients require other supportive treatments to obtain similar clinical improvements. Further studies are needed to devise a criteria for BRVO patients who need additional PSTA. 5.3 Clinical Implications The One and stepped PRN protocol used fewer IVI injections compared to notable studies like BRAVO and VIBRANT. The vessel occlusion in BRVO results in a hypoxic state within the intraocular environment. This triggers the release of several cytokines, including endothelin-1 and VEGF. Such cytokines will promote edematous changes due to increased vascular permeability within the affected intraocular areas. Interestingly, BRVO eyes have been known to adapt to such hypoxic stress through the formation of collateral circulation. However, since VEGF plays an important role in vessel formation, it is still under discussion whether anti-VEGF might theoretically inhibit collateral development. Such impairment on collateral formation by anti-VEGF agents may potentially prolong the duration of the BRVO disease [ 18 ]. One of the main purposes behind our “One and Stepped PRN” protocol was to promote the formation of such collaterals by decreasing the number of anti-VEGF used among BRVO eyes. The other implications of our protocol were that it could also potentially reduce patient burden and improve capacity among ophthalmic clinics[ 19 ]. Examples of treatment burdens include demand on resources, financial cost, travel time by patients, risk of infection during procedure. 5.4 Comparison to other studies Our results showed that patients possessing poorer baseline BCVA were significantly associated with greater gains in BCVA at final follow-up after anti-VEGF treatment. Furthermore, a thicker CRT at baseline was significantly associated with greater CRT improvement at the final follow-up after anti-VEGF treatment. These results were similar to previous published studies[ 6 , 7 , 20 ]. We deduced that participants with thicker CRT and worse BCVA at baseline would have greater opportunities for improvement and are more likely to show improvement in certain anatomical and functional parameters. While age and HTN were associated with a higher risk of developing BRVO, according to the Eye Disease Case-control Study Group (EDCC) study, our findings indicated that such risks did not translate into actual statistical effects on BCVA gains or post-treatment CRT reductions. There are factors that may have influenced our results such as how patient included in the study controlled their medical comorbidities[ 3 ]. These form interesting avenues for future study to further explore. The BRAVO trial investigated clinical effects of ranibizumab on patients with ME after BRVO by six monthly injections of ranibizumab. The average BCVA improvement from BRAVO regarding the ETDRS letter score was 18.3. The average CRT improvement from the 12th month was 347.4 µm. Our results have been comparable to BRAVO regarding average BCVA and CRT improvement. This has clinical implications when considering that the mean amount of IVI used in BRAVO trail is 8.4 injections but for our Group 2 (Ranibizumab) was 3.86. Additionally, it should be noted that our study's CRT improvement seemed less in magnitude compared to the BRAVO trial. However, this hints towards a ceiling effect in terms of CRT improvement as the natural thickness of the fovea has been estimated to be around 230 to 240µm [ 21 ]. Therefore, it can be hypothesized that eyes with thicker CRT would have greater room for CRT improvement. However, differences in study design between ours and BRAVO could make direct comparisons difficult. One example is concerning the difference in treatment threshold for CRT. For example, patients in BRAVO received IVI Ranibizumab only if CRT was greater than 250µm. Comparatively, our treatment threshold was at 300µm. In terms of the VIBRANT trial, their results showed that at 52 weeks, 57.14% of their patients had improvement in BCVA with an average amount of 9 intra-vitreal injections. This was interesting as Group 3(Aflibercept) in our study achieved similar improvement in BCVA while using fewer IVI than the VIBRANT trial (3.73 vs 9). Regarding average CRT improvement, VIBRANT achieved a greater reduction in average CRT compared to ours (283.9 vs 237.67). There have also been other studies that have supported the application of a PRN protocol without a loading dose in the initial stages of BRVO treatment [ 22 – 24 ]. In one study, Chen et al. compared BRVO patients receiving Conbercept under 1 + PRN protocol and 3 + protocol [ 22 ]. They reported that there was no significant difference between the two groups in terms of BCVA and CRT improvement. In another prospective randomized study by Tang et al., the results again validated adopting a treatment protocol that reduces the number of IVI Ranibizumab needed to treat ME [ 23 ]. Our One and Stepped PRN protocol further extend follow up period providing no ME occur. This is still different from treat and extend protocol as no need of IVI during our extending PRN follow up period. Another interesting aspect was that our study reported a median stable condition without ME after the first resolution was around 12 weeks. The results were similar to those of Noma et al., who reported the mean period between the first and second IVI aflibercept was 92.5 ± 40.8 days[ 25 ]. 6. Strength and limitation This is the first real-world data from an Asian country that assessed the outcomes from using a modified PRN protocol to treat naïve BRVO eyes. Furthermore, we also included a multi-regression analysis of predictors that involved anatomical and functional parameters. However, several limitations of our study deserve some discussion. These included no randomized control group, retrospective nature, limited follow-up, inclusion of patients with PSTA treatments, and small sample size. Other limitations include the lack of analysis for laboratory findings such as HbA1c levels, total cholesterol, and other related lipid serum levels. We also did not evaluate for OCT parameters such as the integrity of the ellipsoid zone and inner retinal layers and the effect that macular perfusion status may have on our results. Conclusion In conclusion, we have shown that treatment naïve BRVO eyes treated with One and Stepped PRN protocol significantly improved BCVA and CRT. We also showed that having a worse initial BCVA and CRT predicted further improvements among these functional and anatomical parameters. Furthermore, there was no significant difference in BCVA and CRT improvements between our study and the BRAVO and VIBRANT trials. Declarations Author contributions PYJC, AYH, CTL wrote and edited the main text of the paper. PYJC, CTL participated in the design of the study and drafting of the paper. PYJC, AYH, CTL, CJL, NYH, WLC, PPT, JML, SNC, YYT designed, discussed, edited and guided the overall process of the paper. PYJC, CTL contributed to the drafting of the paper. PYJC, CTL, CJL, WLC, JML, SNC, YYT contributed to the design of the study. PYJC, AYH, CTL, CJL, WLC, JML, SNC, YYT provided valuable insight and contributed to the drafting of the paper. All authors approved the final version of the manuscript and agree to be held accountable for the content therein. Funding/competing interests: The authors did not receive support from any organization for the submitted work. The authors declare they have no financial/Non-financial/competing interests to disclose. Compliance with Ethical Standards This study has been approved by the Medical Center Research Ethics Committee from the China Medical University Hospital (CMUH112-REC1-044). It has been conducted in accordance with the principles of the Declaration of Helsinki. Informed Consent Statement As this study involved a retrospective analysis of deidentified data obtained during routine clinical care, informed consent was waived by the China Medical University Hospital Ethics Committee. Data availability Statement The dataset used for analysis is available from the corresponding authors Chun-Ting Lai under reasonable request. All data used were included as tables and graphs in the current study. References Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol. 1989;107(7):998-1000. Rehak J, Rehak M. Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities. Current Eye Research. 2008;33(2):111-31. Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, et al. [Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study]. J Fr Ophtalmol. 2014;37(6):480-5. Biotech F. FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion. 2010, Jun 22. Ophthalmology AAo. FDA approves Eylea for BRVO 2014, October 8 [Available from: https://www.aao.org/headline/fda-approves-eylea-brvo. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-602. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, et al. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology. 2017;124(12):1778-87. Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016;123(2):330-6. Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. Retina (Philadelphia, Pa). 2021;41(9):1911-20. Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(9):946-55. Hayreh SS, Zimmerman MB. Branch retinal vein occlusion: natural history of visual outcome. JAMA Ophthalmol. 2014;132(1):13-22. Ferrante N, Ritrovato D, Bitonti R, Furneri G. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. BMC Health Serv Res. 2022;22(1):573. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-101.e5. Freund KB, Sarraf D, Leong BCS, Garrity ST, Vupparaboina KK, Dansingani KK. Association of Optical Coherence Tomography Angiography of Collaterals in Retinal Vein Occlusion With Major Venous Outflow Through the Deep Vascular Complex. JAMA Ophthalmology. 2018;136(11):1262-70. Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014;121(12):2432-42. Pichi F, Elbarky AM, Elhamaky TR. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol. 2019;39(1):145-53. Wu WC, Chen JT, Tsai CY, Wu CL, Cheng CK, Shen YD, et al. A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study. BMC Ophthalmol. 2020;20(1):462. Kokolaki AE, Georgalas I, Koutsandrea C, Kotsolis A, Niskopoulou M, Ladas I. Comparative analysis of the development of collateral vessels in macular edema due to branch retinal vein occlusion following grid laser or ranibizumab treatment. Clinical Ophthalmology. 2015;9:1519-22. Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesbøll C. Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway. Clin Ophthalmol. 2023;17:1465-74. Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, et al. Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. PLoS One. 2020;15(6):e0234739. Oderinlo O, Bogunjoko T, Hassan A, Idris O, Dalley A, Oshunkoya L, et al. Normal Central Foveal Thickness in a Thousand Eyes of Healthy Patients in Sub Saharan Africa Using Fourier Domain Optical Coherence Tomography. Nigerian Journal of Clinical Practice. 2023;26(3):331-5. Chen X, Hu TM, Zuo J, Wu H, Liu ZH, Zhan YX, et al. Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections. BMC Ophthalmology. 2020;20(1):225. Tang W, Guo J, Xu G, Liu W, Chang Q. Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study. Ophthalmol Ther. 2022;11(6):2309-20. Inagaki M, Hirano Y, Yasuda Y, Kawamura M, Suzuki N, Yasukawa T, et al. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema. Seminars in Ophthalmology. 2021;36(7):482-9. Noma H, Yasuda K, Narimatsu A, Asakage M, Shimura M. New individualized aflibercept treatment protocol for branch retinal vein occlusion with macular edema. Scientific Reports. 2023;13(1):1536. Tables Demographic variable a Average age, mean(SD) 65.82(10.88) Gender, n(%) Male 14(63.6) Female 8(36.3) Diabetes mellitus, n(%) 9(40.9) Hypertension, n(%) 11(50) Portion receiving PSTA, n(%) 6(27.3) Average follow up duration, weeks, mean(SD) 54.45(7.65) Average number of IVI injections, n, mean(SD) 3.54(1.74) Average number of IVI in first 3 months, n, mean(SD) 2(0.87) Average initial BCVA, ETDRS letter score, mean(SD) 45.86(19.46) Average BCVA improvement, ETDRS letter score, mean(SD) 23.91(17.36), p<0.0001 Average initial CRT, μm, mean(SD) 562.5(164.02) Average CRT improvement, μm, mean(SD) 245.55(153.31), p<0.0001 a: 0 patient in group 1 Table 1. Baseline Demographics and clinical outcomes. Abbreviations: BCVA, best-corrected distance visual acuity; CRT, central retinal thickness; IVI, intravitreal injection; PSTA, posterior sub-tenon’s triamcinolone acetonide; SD, standard deviation. Group 2 (First Bevacizumab and then Ranibizumab or all Ranibizumab) n=7 Group 3 (First Bevacizumab and then Aflibercept or all Aflibercept) n=15 P value a Average amount of IVI 3.86(1.95) 3.73(1.58) P=0.87 Average initial BCVA, ETDRS letter score, mean(SD) 55.43(20.92) 41.4(17.71) P=0.12 Average BCVA improvement, ETDRS letter score, mean(SD) 18.43(16.95) 26.47(17.52) P=0.93 Average initial CRT, μm, mean(SD) 548.29(231.64) 516.33(130.41) P=0.68 Average CRT improvement, μm, mean(SD) 262.43(197.38) 237.67(135.46) P=0.27 a: two sample t-test Table 2. baseline characteristics and treatment effects among classified groups. Abbreviations: BCVA, best-corrected distance visual acuity; CRT, central retina thickness; IVI, intravitreal injection Crude association, p value Adjusted association, p value Improvement in BCVA Initial BCVA(ETDRS letters) 0.08 0.030* Age 0.457 0.832 Time from symptoms to treatment 0.987 0.272 Diabetes mellitus 0.182 0.15 Hypertension 0.505 0.448 Improvement in CRT Initial CRT <0.001* <0.001* Age 0.479 0.978 Time from symptoms to treatment 0.038* 0.146 Diabetes mellitus 0.356 0.575 Hypertension 0.604 0.058 *: p value≦0.05 Table 3. Association between clinical factors and improvement in either BCVA or CRT. Abbreviations: BCVA, Best Corrected Visual Acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study Group 2 (First Bevacizumab and then Ranibizumab or all Ranibizumab) n=7 BRAVO 12 months trial N=131 P value a Average amount of IVI 3.86(1.95) 8.4(-) b - Average initial BCVA, ETDRS letter score, mean(SD) 55.43(20.92) 53.0(12.5) P=0.77 Average BCVA improvement, ETDRS letter score, mean(SD) 18.43(16.95) 18.3(14.89) P=0.98 Average initial CRT, μm, mean(SD) 548.29(231.64) 551.7(223.5) P=0.97 Average CRT improvement, μm, mean(SD) 262.43(197.38) 347.4(-) b - a: two sample t-test b: inadequate information to obtain standard deviation Table 4. baseline characteristics and treatment effects between Group 2 and BRAVO 12 months trial. Abbreviation: BCVA, best corrected visual acuity; CRT, central retinal thickness; IVI, intravitreal injection Group 3 (First Bevacizumab and then Aflibercept or all Aflibercept) n=15 VIBRANT 52weeks trial N=91 Average amount of IVI 3.73(1.58) 9.0(1.8) P<0.0001 a Portion of patients with improvement <15ETDRS letters(%) 2(13.33%) 32(35.16%) P=0.223 b Portion of patients with improvement≧15 ETDRS letters(%) 12(80%) 52(57.14%) Portion of patients with ETDRS letters loss(%) 1(6.67%) 7(7.7%) Average initial CRT, μm, mean(SD) 516.33(130.41) - c - c Average CRT improvement, μm, mean(SD) 237.67(135.46) 283.9(-) c - c a: two sample t-test b: Fisher's exact test c: not available data for further calculation Table 5. baseline characteristics and treatment effects between Group 2 and VIBRANT 52weeks trial. Abbreviation: IVI, intravitreal injection Group 3 (First Bevacizumab and then Aflibercept or all Aflibercept) n=15 VIBRANT 52weeks trial N=91 Average amount of IVI 3.73(1.58) 9.0(1.8) P<0.0001 a Portion of patients with improvement <5ETDRS letters(%) 2 4 P=0.265 b Portion of patients with improvement 5~9ETDRS letters(%) 1 7 Portion of patients with improvement 10~14ETDRS letters(%) 1 21 Portion of patients with improvement 15~29ETDRS letters(%) 10 39 Portion of patients with improvement≧30 ETDRS letters(%) 7 13 Portion of patients with ETDRS letters loss <5ETDRS letters (%) 0 2 Portion of patients with ETDRS letters loss 5~9ETDRS letters(%) 1 2 Portion of patients with ETDRS letters loss 10~14ETDRS letters(%) 0 1 Portion of patients with ETDRS letters loss≧15 ETDRS letters(%) 0 2 a: two sample t-test b: Fisher's exact test Table 6. baseline characteristics and treatment effects between Group 2 and VIBRANT 52weeks trial (detailed version). Abbreviation: IVI, intravitreal injection Additional Declarations No competing interests reported. Supplementary Files supplementarymaterialbrvopoyu.docx visualabstract.png Cite Share Download PDF Status: Published Journal Publication published 14 Aug, 2025 Read the published version in Medicine → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4478566","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":312336619,"identity":"527610b2-2458-459b-b72c-d26a20f3d356","order_by":0,"name":"Po-Yu(Jay) Chen","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Po-Yu(Jay)","middleName":"","lastName":"Chen","suffix":""},{"id":312336620,"identity":"f132842d-3f53-4240-a8b3-5d6457afe93d","order_by":1,"name":"Alan Y. Hsu","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Alan","middleName":"Y.","lastName":"Hsu","suffix":""},{"id":312336621,"identity":"45ba4bc6-bd4b-4106-a5ff-6f1111c72d88","order_by":2,"name":"Chun-Ting Lai","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA90lEQVRIiWNgGAWjYDACZgY2BgYDBsY2/v6PDxgYDhCjhRmipV/igLEBkhYDfHrYQCTjzIYEMwmitBgc5z/2mKfgjuyGAwfSqnlq7sjxMzA/fHSD4U9iAy4th5nZjXkMnhlvONxw7DbPsWfGkg1sxsY5DAY4tZgdZmaTzjE4nLjhwMG22zxsIAYPUITBIJcILclsxTz/SNEysyGNjZm3jQgt9oeZzaT/GBw27pc4wyw5t++wsWQzyC8GxvW4tEj2H3wmOePPYdk2/h7GD2++HZbjZ29++DinQs4Yhw5UwMQDIplBBL6YRAaMP4hUOApGwSgYBSMLAABjplh0G11SKgAAAABJRU5ErkJggg==","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":true,"prefix":"","firstName":"Chun-Ting","middleName":"","lastName":"Lai","suffix":""},{"id":312336622,"identity":"c705ac0a-4a6f-45ab-a69f-150d268ea672","order_by":3,"name":"Chun-Ju Lin","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Chun-Ju","middleName":"","lastName":"Lin","suffix":""},{"id":312336623,"identity":"3c7d704f-9202-401a-a848-b07957677221","order_by":4,"name":"Ning-Yi Hsia","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ning-Yi","middleName":"","lastName":"Hsia","suffix":""},{"id":312336624,"identity":"c0faa1c1-5bda-40b6-8f24-2d636ec4c5b2","order_by":5,"name":"Wen-Lu Chen","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Wen-Lu","middleName":"","lastName":"Chen","suffix":""},{"id":312336625,"identity":"4f6286a7-cd33-4927-a61d-4fd998ebf747","order_by":6,"name":"Peng-Tai Tien","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Peng-Tai","middleName":"","lastName":"Tien","suffix":""},{"id":312336626,"identity":"e1cb29a8-7cf2-405b-85a8-0c4cc1e74da5","order_by":7,"name":"Jane-Ming Lin","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Jane-Ming","middleName":"","lastName":"Lin","suffix":""},{"id":312336627,"identity":"d8afdc0c-5f7e-4da7-bb43-7c4399de68a5","order_by":8,"name":"San-Ni Chen","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"San-Ni","middleName":"","lastName":"Chen","suffix":""},{"id":312336628,"identity":"eafa772c-a057-4e27-91ed-842d9db2ff19","order_by":9,"name":"Yi-Yu Tsai","email":"","orcid":"","institution":"Eye Center, China Medical University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yi-Yu","middleName":"","lastName":"Tsai","suffix":""}],"badges":[],"createdAt":"2024-05-26 04:08:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4478566/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4478566/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1097/MD.0000000000043931","type":"published","date":"2025-08-15T00:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":58225254,"identity":"f351d186-1713-41b2-8285-cfd66fb73103","added_by":"auto","created_at":"2024-06-12 17:44:29","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":137607,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan-Meier plot of the incidence of recurrence for BRVO patients who received resolution. \u003cbr\u003e\nDotted line: median time of stable condition without macular edema after first resolution. (12 weeks)\u003c/p\u003e","description":"","filename":"Fig1.png","url":"https://assets-eu.researchsquare.com/files/rs-4478566/v1/4a869b58a6c9ac260ef9b068.png"},{"id":90613927,"identity":"3ebf734b-cc78-402d-801b-d58a19170920","added_by":"auto","created_at":"2025-09-04 17:50:13","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":992513,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4478566/v1/d5c88b58-d74b-49b9-abad-1dba3bfbcf77.pdf"},{"id":58225257,"identity":"dc52f01f-f346-4d2c-9b75-a2b9ab76af1a","added_by":"auto","created_at":"2024-06-12 17:44:30","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":169733,"visible":true,"origin":"","legend":"","description":"","filename":"supplementarymaterialbrvopoyu.docx","url":"https://assets-eu.researchsquare.com/files/rs-4478566/v1/f71acf2ce1f6a376caf08dbd.docx"},{"id":58225255,"identity":"aa37648c-f2ae-4269-815c-fd50314ea437","added_by":"auto","created_at":"2024-06-12 17:44:30","extension":"png","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":606817,"visible":true,"origin":"","legend":"","description":"","filename":"visualabstract.png","url":"https://assets-eu.researchsquare.com/files/rs-4478566/v1/554561c98b225f1187b15190.png"}],"financialInterests":"No competing interests reported.","formattedTitle":"Comparing the effectiveness of treating branch retinal vein occlusion with a novel One and Stepped Pro Re Nata treatment protocol","fulltext":[{"header":"Introduction","content":"\u003cp\u003eBranch retinal vein occlusion (BRVO) is the occlusion of the retinal veins branches due to mechanical compression, vessel wall degeneration, or hypercoagulative status[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. One of the leading causes of reduction in visual acuity among BRVO patients is macular edema (ME) [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. The other complications of BRVO can include neovascular development. This can result in vitreous haemorrhage, tractional retinal detachment, or neovascular glaucoma.\u003c/p\u003e \u003cp\u003eIntravitreal injection(IVI) of Anti-vascular endothelial growth factor (anti-VEGF) therapies become the mainstay treatment to manage BRVO eyes after being approved by the Food and Drug Administration (FDA) of the United States between 2010 and 2014[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Several trials have supported the clinical utility of anti-VEGF for BRVO patients. This includes the BRAVO study(monthly injection for 6 months and received injection if needed during month 6\u0026ndash;11), the BRIGHTER study(In the Ranibizumab monotherapy arm, at least three monthly injections was given until vision was stable. The next retreatment will started only when vision decreased due to disease activity during monthly exam.), and the VIBRANT study (In the IVI group, injections were given every 4 weeks until week 24 and then every 8 weeks until week 48 with rescue grid laser if needed at week 36.) [\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Most of the protocols of these studies started with a 3\u0026ndash;6 monthly injection as loading phase regardless of edema condition, then proceeded with different follow up protocols. Despite their clear benefits, frequent anti-VEGF therapies may constitute a burden, including a financial burden and the risk of infection, for both patients and clinicians alike.\u003c/p\u003e \u003cp\u003eIn order to adjust to real world burden, protocols like Treat \u0026amp; Extend and PRN developed from treating age-related macular degeneration (AMD) and diabetic macular edema(DME) were applied to treat BRVO[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. However, studies have reported that BRVO patients received no treatment could still achieve good outcomes [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. This was described in a review that reported improvement in the visual acuity [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] among those with untreated BRVO eyes [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Such clinical results obtained from untreated BRVO eyes have been hypothesized to be due to the formation of collateral circulation as an adaption to bypass the total capillary bed obstruction seen among BRVO eyes [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Such collaterals can salvage residual retina function as well as decrease the occurrence of edema. This indicates a good prognosis from the perspective of pathophysiology and hemodynamics of BRVO.\u003c/p\u003e \u003cp\u003eUnder the finding that certain portions of patients under natural clinical course with good outcomes combined with the evidence of the collateral vessel maturation which is different from AMD and DME, this raise the question of whether we truly need that many injections of IVI-antiVEGF and whether these patients really require monthly follow-up. Unfortunately, available evidence on the different PRN protocols for BRVO eyes has been limited by their variability in study designs and protocols. For example, there was a lack of consensus on the use of a loading dose[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] as well as the clinical indications for IVI usage[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Also, none of these studies assessed the outcomes of extending the follow-up period instead of monthly intervals.\u003c/p\u003e \u003cp\u003eThis study aimed to assess the anatomical and functional outcomes of BRVO eyes with ME treated with our novel \u0026ldquo;One and Stepped PRN\u0026rdquo; anti-VEGF IVI protocol. We also sought to compare the efficacy of our novel PRN protocol with results from the BRAVO and VIBRANT trials.\u003c/p\u003e"},{"header":"Material and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Study population\u003c/h2\u003e \u003cp\u003eThis retrospective and single institutional study involved the evaluation of electronic medical records of treatment na\u0026iuml;ve BRVO patients undergoing our proposed \u0026ldquo;One and Stepped PRN\u0026rdquo; anti-VEGF protocol. All patients underwent a routine ophthalmic examination at every visit. This included best-corrected visual acuity (BCVA) assessment and evaluation by spectral-domain optical coherence tomography (SD-OCT; Heidelberg Engineering, Heidelberg, Germany). The study period was from January 2016 to October 2022. This study has been approved by the Medical Center Research Ethics Committee from the China Medical University Hospital (CMUH112-REC1-044). It has been conducted in accordance with the principles of the Declaration of Helsinki. Due to the use of anonymized data obtained during routine clinical care, the informed consent was waived by the Ethics Committee\u0026rsquo;s approval.\u003c/p\u003e \u003cp\u003eThe inclusion criteria included patients of all ages diagnosed with BRVO and followed up for at least a year between January 2016 and October 2022. Furthermore, we only recruited patients with BRVO who received at least one dose of anti-VEGF within the study period.\u003c/p\u003e \u003cp\u003eThe exclusion criteria included patients with a history of other ocular diseases, including retina diseases (e.g., diabetic retinopathy and age-related macular degeneration). We also excluded those with a previous history of any anti-VEGF IVI therapies. However, if cataracts developed during the follow-up period, we only excluded them if the patient did not receive cataract surgery before the end of the follow-up time. Also, we only excluded patients with epiretinal membrane located within the parafovea (central 2.5mm in diameter).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Treatment Regime\u003c/h2\u003e \u003cp\u003eOur proposed \u0026ldquo;One and Stepped PRN\u0026rdquo; protocol for BRVO patients consisted of two phases: 1) a monthly treatment phase and 2) a stepped PRN phase. BRVO patients found to have ME will receive IVI of anti-VEGF during monthly follow up until the edema was resolved. When the ME has been resolved, the patient will be shifted to the stepped PRN phase of the protocol. As part of this modified PRN phase of the protocol, patients will initially return one month after the last IVI injection. This is followed by two months, then three months, until the maximum of 4 months after the initial date was reached (see \u003cb\u003eSupplementary Fig.\u0026nbsp;1\u003c/b\u003e). Unlike treat and extend protocol, IVI was not given during all of these follow up time. However, if there was a re-occurrence of ME, monthly treatment of IVI anti-VEGF will be reinitiated until another resolution of ME is achieved one month after the last injection. The next follow-up period would be the longest interval the patient has had previously. ME for our study was defined as choroidal retinal thickness (CRT) greater than 300\u0026micro;m assessed by OCT or the presence of other evidence of intraretinal fluid (IRF) or subretinal fluid(SRF).\u003c/p\u003e \u003cp\u003eTo analyze the effects of different anti-VEGF IVI therapies, we classified our patients into three groups based on their treatment. Group 1 was composed of BRVO patients who only received Bevacizumab (Avastin) injections. Group 2 are patients who either received Ranibizumab (Lucentis) only or received Bevacizumab first and then Ranibizumab. Regarding Group 3, we classified patients who either received Aflibercept (Eylea) only or received Bevacizumab first and then Aflibercept. The reimbursement policy of the Taiwan National Health Insurance towards anti-VEGF IVI usage influenced the organization of our three treatment subgroups. To qualify for anti-VEGF IVI reimbursements, patients must first undergo review by the Taiwan National Health Insurance[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Therefore, Taiwanese patients often opt to self-pay for Bevacizumab treatment during this review period as a cost containment option [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Outcome Measures\u003c/h2\u003e \u003cp\u003eThe primary outcome of interest was the mean change from baseline BCVA recorded via Early Treatment Diabetic Retinopathy Study (ETDRS) letters and CRT changes assessed by OCT.\u003c/p\u003e \u003cp\u003eIn terms of baseline demographics, we collected factors such as age, certain medical comorbidities such as hypertension (HTN) and diabetes mellitus (DM) status, initial best-corrected distance visual acuity (BCVA), and central retina thickness (CRT). Other variables of interest included the total number of IVIs received, the final BCVA, and CRT.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003e3. Statistical analysis\u003c/h3\u003e\n\u003cp\u003eBCVA changes and CRT changes were calculated and compared by paired t-test. Sub-group analyses were classified based on the type of IVI and the presence of DM and HTN. Continuous variables were displayed by means and standard deviations (SD). Categorical variables were displayed by portion and percentage. The Kaplan-Meier plot displayed the incidence of recurrence. Results from our study were compared with previous trials (BRAVO [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e] and VIBRANT[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]). Student\u0026rsquo;s t-test with unequal variance was conducted for continuous data and chi-square test and Fisher's exact test for categorical data. Regression analyses were performed to evaluate the potential risk factors.\u003c/p\u003e \u003cp\u003eAll statistical analyses were two-tailed, and statistically significant results were considered when the p-value was less than 0.05. STATA 1.4.2 was used for statistical analysis.\u003c/p\u003e"},{"header":" Results","content":"\u003cp\u003e\u003cstrong\u003e4.1 Baseline Data\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe demographic data is shown in \u003cstrong\u003eTable 1\u003c/strong\u003e. 22 treatment na\u0026iuml;ve BRVO eyes (36.3% female; average age 65.82 \u003cem\u003e+/-\u003c/em\u003e 10.8 years) were recruited for this study. Regarding anti-VEGF IVI therapies, none of our patients received Bevacizumab (Group 1) only. Seven patients received Ranibizumab as their primary treatment (and were listed under Group 2). Fifteen patients received Aflibercept as their primary treatment (and were listed under Group 3). The average follow-up duration was 54.45 +/- 7.65 weeks. 9 (40.9%) of our patients had DM, and 11 (50%) had HTN at baseline. The average BCVA at baseline was 45.86 \u0026plusmn; 19.46 ETDRS letters, and the average initial CRT at baseline was 526.5 \u0026plusmn; 164.02 \u0026mu;m.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e4.2 Treatment effects \u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong our 22 patients recruited for this study, 7 received Ranibizumab (Group 2) as part of their anti-VEGF therapy, and 15 received Aflibercept (Group 3) as part of their anti-VEGF therapy. None of our patients received Bevacizumab only (Group 1) (see \u003cstrong\u003eTable 2\u003c/strong\u003e). No significant statistical difference was found between the patients from Group 2 and Group 3 in terms of initial BCVA (p=0.12), initial CRT (p=0.93), and the improvement of BCVA (p=0.93) and CRT (p=0.27) (see \u003cstrong\u003eTable 2\u003c/strong\u003e). \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe average injections of anti-VEGF given were 3.54 \u0026plusmn; 1.74 (2\u0026plusmn;0.87 in the first three months) (see \u003cstrong\u003eTable 1\u003c/strong\u003e). The overall average BCVA improvement was 23.91 \u0026plusmn; 17.36 ETDRS letters (p\u0026lt;0.0001), and the overall average CRT improvement was 245.55 \u0026plusmn; 153.31 \u0026mu;m (p\u0026lt;0.0001) (see \u003cstrong\u003eTable 1\u003c/strong\u003e). Figure 1 shows the Kaplan-Meier survival curve (see \u003cstrong\u003eFig. 1\u003c/strong\u003e) for all eyes recruited. Our Kaplan-Meier curve revealed a median of 12 weeks of stable condition without ME after the first resolution.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePatients receiving PSTA had baseline BCVA that was worse than those who didn\u0026rsquo;t receive PSTA (31.38\u0026plusmn;6.26 vs. 54.14\u0026plusmn;4.14, p=0.005). However, initial CRT (p=0.41), BCVA improvement (p=0.80) and CRT improvement (p=0.69) did not significantly differ between these two groups.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e4.3 Multivariable regression analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMultivariable regression analysis was also performed to determine what factors may influence the improvement of final BCVA and CRT parameters compared to the baseline. We found that the initial baseline BCVA was a statistically significant negative predictor for improvement in BCVA at the final follow-up (p=0.030). In other words, patients with worse baseline BCVA reported more improvement in BCVA at follow-up. We also found that the initial CRT was a statistically significant predictor for improvement in CRT at the final follow-up (p\u0026lt;0.001). In other words, patients with higher baseline CRT reported more improvements in terms of CRT at the final follow-up (see \u003cstrong\u003eTable 3\u003c/strong\u003e). The factors of age, time from symptoms onset, and associated medical comorbidities of DM and HTN were found to have no significant effect on the overall BCVA and CRT improvement from baseline.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e4.4 Statistical comparisons with other trials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSeveral clinical parameters were compared between our results and the two previously published anti-VEGF-related trials (the BRAVO and VIBRANT study). The compared parameters included the average amount of IVI used, average initial and improvement in BCVA, and average initial and improvement in CRT.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCompared to the BRAVO study[6], the number of anti-VEGF injections used within the first year from our Group 2 (Ranibizumab) participants was significantly lower in number (8.4 vs. 3.86\u0026plusmn;1.95, no SD in BRAVO for p-value calculation). In terms of other parameters of interest, there was no significant difference in initial BCVA between the BRAVO study and our group 2 participants (53.0\u0026plusmn;12.5 vs. 55.43\u0026plusmn;20.92, p=0.77), initial CRT (551.7\u0026plusmn;223.5 vs. 548.29\u0026plusmn;231.64, p=0.97), BCVA improvement (18.3\u0026plusmn;14.89 vs. 18.43\u0026plusmn;16.95, p=0.98) and CRT improvement (347.4 vs. 262.43, no SD in BRAVO for p-value calculation) (see \u003cstrong\u003eTable 4\u003c/strong\u003e).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCompared to the VIBRANT 52 weeks study [8], the number of anti-VEGF injections received was significantly more than our Group 3 (Aflibercept) participants (9.0\u0026plusmn;1.8 vs. 3.73\u0026plusmn;1.58, p\u0026lt;0.0001). Regarding the proportion of patients with different degree of vision gain or vision loss, we found no significant difference between VIBRANT and our Group 3 (p=0.223) (see \u003cstrong\u003eTable 5\u0026nbsp;\u003c/strong\u003eand \u003cstrong\u003eTable 6\u003c/strong\u003e). Regarding other parameters of interest (e.g., initial BCVA and CRT), there was insufficient baseline data from the VIBRANT trial to calculate any statistical comparisons.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis was a novel retrospective case series to investigate the effects of our novel \u0026ldquo;One and Stepped PRN\u0026rdquo; anti-VEGF protocol over na\u0026iuml;ve BRVO eyes.\u003c/p\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e5.1 Novel findings\u003c/h2\u003e \u003cp\u003eWe found that the One and Stepped PRN anti-VEGF protocol significantly improved average BCVA and average CRT. The results also revealed a median stable condition in terms of no ME after the first resolution after 12 weeks. Furthermore, anatomical and functional parameters assessed within our study did not significantly differ among the different anti-VEGF agents used (i.e., Bevacizumab, Ranibizumab, and Aflibercept). Our multivariable regression analysis also revealed that initial BCVA and initial CRT have significantly affected final BCVA and CRT improvements, respectively.\u003c/p\u003e \u003cp\u003eIn terms of PSTA, this was designed as an adjuvant therapy for those with a relatively worse initial condition. This could be seen from our results, as the PSTA group reported worse initial BCVA but had similar gains in improvements (BCVA and CRT) at final follow-up. This indicated that such patients require other supportive treatments to obtain similar clinical improvements. Further studies are needed to devise a criteria for BRVO patients who need additional PSTA.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e5.3 Clinical Implications\u003c/h2\u003e \u003cp\u003eThe One and stepped PRN protocol used fewer IVI injections compared to notable studies like BRAVO and VIBRANT. The vessel occlusion in BRVO results in a hypoxic state within the intraocular environment. This triggers the release of several cytokines, including endothelin-1 and VEGF. Such cytokines will promote edematous changes due to increased vascular permeability within the affected intraocular areas. Interestingly, BRVO eyes have been known to adapt to such hypoxic stress through the formation of collateral circulation. However, since VEGF plays an important role in vessel formation, it is still under discussion whether anti-VEGF might theoretically inhibit collateral development. Such impairment on collateral formation by anti-VEGF agents may potentially prolong the duration of the BRVO disease [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. One of the main purposes behind our \u0026ldquo;One and Stepped PRN\u0026rdquo; protocol was to promote the formation of such collaterals by decreasing the number of anti-VEGF used among BRVO eyes. The other implications of our protocol were that it could also potentially reduce patient burden and improve capacity among ophthalmic clinics[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Examples of treatment burdens include demand on resources, financial cost, travel time by patients, risk of infection during procedure.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003e5.4 Comparison to other studies\u003c/h2\u003e \u003cp\u003eOur results showed that patients possessing poorer baseline BCVA were significantly associated with greater gains in BCVA at final follow-up after anti-VEGF treatment. Furthermore, a thicker CRT at baseline was significantly associated with greater CRT improvement at the final follow-up after anti-VEGF treatment. These results were similar to previous published studies[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. We deduced that participants with thicker CRT and worse BCVA at baseline would have greater opportunities for improvement and are more likely to show improvement in certain anatomical and functional parameters.\u003c/p\u003e \u003cp\u003eWhile age and HTN were associated with a higher risk of developing BRVO, according to the Eye Disease Case-control Study Group (EDCC) study, our findings indicated that such risks did not translate into actual statistical effects on BCVA gains or post-treatment CRT reductions. There are factors that may have influenced our results such as how patient included in the study controlled their medical comorbidities[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. These form interesting avenues for future study to further explore.\u003c/p\u003e \u003cp\u003eThe BRAVO trial investigated clinical effects of ranibizumab on patients with ME after BRVO by six monthly injections of ranibizumab. The average BCVA improvement from BRAVO regarding the ETDRS letter score was 18.3. The average CRT improvement from the 12th month was 347.4 \u0026micro;m. Our results have been comparable to BRAVO regarding average BCVA and CRT improvement. This has clinical implications when considering that the mean amount of IVI used in BRAVO trail is 8.4 injections but for our Group 2 (Ranibizumab) was 3.86.\u003c/p\u003e \u003cp\u003eAdditionally, it should be noted that our study's CRT improvement seemed less in magnitude compared to the BRAVO trial. However, this hints towards a ceiling effect in terms of CRT improvement as the natural thickness of the fovea has been estimated to be around 230 to 240\u0026micro;m [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Therefore, it can be hypothesized that eyes with thicker CRT would have greater room for CRT improvement. However, differences in study design between ours and BRAVO could make direct comparisons difficult. One example is concerning the difference in treatment threshold for CRT. For example, patients in BRAVO received IVI Ranibizumab only if CRT was greater than 250\u0026micro;m. Comparatively, our treatment threshold was at 300\u0026micro;m.\u003c/p\u003e \u003cp\u003eIn terms of the VIBRANT trial, their results showed that at 52 weeks, 57.14% of their patients had improvement in BCVA with an average amount of 9 intra-vitreal injections. This was interesting as Group 3(Aflibercept) in our study achieved similar improvement in BCVA while using fewer IVI than the VIBRANT trial (3.73 vs 9). Regarding average CRT improvement, VIBRANT achieved a greater reduction in average CRT compared to ours (283.9 vs 237.67).\u003c/p\u003e \u003cp\u003eThere have also been other studies that have supported the application of a PRN protocol without a loading dose in the initial stages of BRVO treatment [\u003cspan additionalcitationids=\"CR23\" citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. In one study, Chen et al. compared BRVO patients receiving Conbercept under 1\u0026thinsp;+\u0026thinsp;PRN protocol and 3\u0026thinsp;+\u0026thinsp;protocol [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. They reported that there was no significant difference between the two groups in terms of BCVA and CRT improvement. In another prospective randomized study by Tang et al., the results again validated adopting a treatment protocol that reduces the number of IVI Ranibizumab needed to treat ME [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Our One and Stepped PRN protocol further extend follow up period providing no ME occur. This is still different from treat and extend protocol as no need of IVI during our extending PRN follow up period. Another interesting aspect was that our study reported a median stable condition without ME after the first resolution was around 12 weeks. The results were similar to those of Noma et al., who reported the mean period between the first and second IVI aflibercept was 92.5\u0026thinsp;\u0026plusmn;\u0026thinsp;40.8 days[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003e6. Strength and limitation\u003c/h3\u003e\n\u003cp\u003eThis is the first real-world data from an Asian country that assessed the outcomes from using a modified PRN protocol to treat na\u0026iuml;ve BRVO eyes. Furthermore, we also included a multi-regression analysis of predictors that involved anatomical and functional parameters. However, several limitations of our study deserve some discussion. These included no randomized control group, retrospective nature, limited follow-up, inclusion of patients with PSTA treatments, and small sample size. Other limitations include the lack of analysis for laboratory findings such as HbA1c levels, total cholesterol, and other related lipid serum levels. We also did not evaluate for OCT parameters such as the integrity of the ellipsoid zone and inner retinal layers and the effect that macular perfusion status may have on our results.\u003c/p\u003e"},{"header":" Conclusion","content":"\u003cp\u003eIn conclusion, we have shown that treatment na\u0026iuml;ve BRVO eyes treated with One and Stepped PRN protocol significantly improved BCVA and CRT. We also showed that having a worse initial BCVA and CRT predicted further improvements among these functional and anatomical parameters. Furthermore, there was no significant difference in BCVA and CRT improvements between our study and the BRAVO and VIBRANT trials.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAuthor contributions\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePYJC, AYH, CTL wrote and edited the main text of the paper.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePYJC, CTL participated in the design of the study and drafting of the paper.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePYJC, AYH, CTL, CJL, NYH, WLC, PPT, JML, SNC, YYT designed, discussed, edited and guided the overall process of the paper.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePYJC, CTL contributed to the drafting of the paper.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePYJC, CTL, CJL, WLC, JML, SNC, YYT contributed to the design of the study.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePYJC, AYH, CTL, CJL, WLC, JML, SNC, YYT provided valuable insight and contributed to the drafting of the paper. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAll authors approved the final version of the manuscript and agree to be held accountable for the content therein.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding/competing interests:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors did not receive support from any organization for the submitted work. The authors declare they have no financial/Non-financial/competing interests to disclose.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompliance with Ethical Standards\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study has been approved by the Medical Center Research Ethics Committee from the China Medical University Hospital (CMUH112-REC1-044). It has been conducted in accordance with the principles of the Declaration of Helsinki.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInformed Consent Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs this study involved a retrospective analysis of deidentified data obtained during routine clinical care, informed consent was waived by the China Medical University Hospital Ethics Committee.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe dataset used for analysis is available from the corresponding authors Chun-Ting Lai under reasonable request. All data used were included as tables and graphs in the current study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eDuker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol. 1989;107(7):998-1000.\u003c/li\u003e\n\u003cli\u003eRehak J, Rehak M. Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities. Current Eye Research. 2008;33(2):111-31.\u003c/li\u003e\n\u003cli\u003eGuigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, et al. [Multicenter Ozurdex\u0026reg; assessment for diabetic macular edema: MOZART study]. J Fr Ophtalmol. 2014;37(6):480-5.\u003c/li\u003e\n\u003cli\u003eBiotech F. FDA Approves Lucentis\u0026reg; (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion. 2010, Jun 22.\u003c/li\u003e\n\u003cli\u003eOphthalmology AAo. FDA approves Eylea for BRVO 2014, October 8 [Available from: https://www.aao.org/headline/fda-approves-eylea-brvo.\u003c/li\u003e\n\u003cli\u003eBrown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-602.\u003c/li\u003e\n\u003cli\u003eTadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, et al. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology. 2017;124(12):1778-87.\u003c/li\u003e\n\u003cli\u003eClark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016;123(2):330-6.\u003c/li\u003e\n\u003cli\u003eMitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. Retina (Philadelphia, Pa). 2021;41(9):1911-20.\u003c/li\u003e\n\u003cli\u003eBrown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(9):946-55.\u003c/li\u003e\n\u003cli\u003eHayreh SS, Zimmerman MB. Branch retinal vein occlusion: natural history of visual outcome. JAMA Ophthalmol. 2014;132(1):13-22.\u003c/li\u003e\n\u003cli\u003eFerrante N, Ritrovato D, Bitonti R, Furneri G. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. BMC Health Serv Res. 2022;22(1):573.\u003c/li\u003e\n\u003cli\u003eRogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-101.e5.\u003c/li\u003e\n\u003cli\u003eFreund KB, Sarraf D, Leong BCS, Garrity ST, Vupparaboina KK, Dansingani KK. Association of Optical Coherence Tomography Angiography of Collaterals in Retinal Vein Occlusion With Major Venous Outflow Through the Deep Vascular Complex. JAMA Ophthalmology. 2018;136(11):1262-70.\u003c/li\u003e\n\u003cli\u003eCampochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014;121(12):2432-42.\u003c/li\u003e\n\u003cli\u003ePichi F, Elbarky AM, Elhamaky TR. Outcome of \u0026quot;treat and monitor\u0026quot; regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol. 2019;39(1):145-53.\u003c/li\u003e\n\u003cli\u003eWu WC, Chen JT, Tsai CY, Wu CL, Cheng CK, Shen YD, et al. A 12-month, prospective, observational study of ranibizumab in treatment-na\u0026iuml;ve Taiwanese patients with neovascular age-related macular degeneration: the RACER study. BMC Ophthalmol. 2020;20(1):462.\u003c/li\u003e\n\u003cli\u003eKokolaki AE, Georgalas I, Koutsandrea C, Kotsolis A, Niskopoulou M, Ladas I. Comparative analysis of the development of collateral vessels in macular edema due to branch retinal vein occlusion following grid laser or ranibizumab treatment. Clinical Ophthalmology. 2015;9:1519-22.\u003c/li\u003e\n\u003cli\u003eReitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesb\u0026oslash;ll C. Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway. Clin Ophthalmol. 2023;17:1465-74.\u003c/li\u003e\n\u003cli\u003ePearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, et al. Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. PLoS One. 2020;15(6):e0234739.\u003c/li\u003e\n\u003cli\u003eOderinlo O, Bogunjoko T, Hassan A, Idris O, Dalley A, Oshunkoya L, et al. Normal Central Foveal Thickness in a Thousand Eyes of Healthy Patients in Sub Saharan Africa Using Fourier Domain Optical Coherence Tomography. Nigerian Journal of Clinical Practice. 2023;26(3):331-5.\u003c/li\u003e\n\u003cli\u003eChen X, Hu TM, Zuo J, Wu H, Liu ZH, Zhan YX, et al. Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections. BMC Ophthalmology. 2020;20(1):225.\u003c/li\u003e\n\u003cli\u003eTang W, Guo J, Xu G, Liu W, Chang Q. Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study. Ophthalmol Ther. 2022;11(6):2309-20.\u003c/li\u003e\n\u003cli\u003eInagaki M, Hirano Y, Yasuda Y, Kawamura M, Suzuki N, Yasukawa T, et al. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema. Seminars in Ophthalmology. 2021;36(7):482-9.\u003c/li\u003e\n\u003cli\u003eNoma H, Yasuda K, Narimatsu A, Asakage M, Shimura M. New individualized aflibercept treatment protocol for branch retinal vein occlusion with macular edema. Scientific Reports. 2023;13(1):1536.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eDemographic variable\u003csup\u003ea\u003c/sup\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage age, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e65.82(10.88)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eGender, n(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e14(63.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e8(36.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eDiabetes mellitus, n(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e9(40.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension, n(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e11(50)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003ePortion receiving PSTA, n(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e6(27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage follow up duration, weeks, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e54.45(7.65)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage number of IVI injections, n, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e3.54(1.74)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage number of IVI in first 3 months, n, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e2(0.87)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage initial BCVA,\u003cbr\u003eETDRS letter score, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e45.86(19.46)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage BCVA improvement,\u003c/p\u003e\n \u003cp\u003eETDRS letter score, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e23.91(17.36), p\u0026lt;0.0001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage initial CRT, \u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e562.5(164.02)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"61.482820976491865%\" valign=\"top\"\u003e\n \u003cp\u003eAverage CRT improvement, \u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"38.517179023508135%\" valign=\"top\"\u003e\n \u003cp\u003e245.55(153.31), p\u0026lt;0.0001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ea: 0 patient in group 1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1. Baseline Demographics and clinical outcomes.\u003c/strong\u003e Abbreviations: BCVA, best-corrected distance visual acuity; CRT, central retinal thickness; IVI, intravitreal injection; PSTA, posterior sub-tenon\u0026rsquo;s triamcinolone acetonide; SD, standard deviation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"680\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003eGroup 2\u003cbr\u003e\u0026nbsp;(First Bevacizumab and then Ranibizumab or all Ranibizumab)\u003cbr\u003e\u0026nbsp;n=7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003eGroup 3\u003cbr\u003e\u0026nbsp;(First Bevacizumab and\u0026nbsp;\u003cbr\u003e\u0026nbsp;then Aflibercept or all Aflibercept)\u003c/p\u003e\n \u003cp\u003en=15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP value\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage amount of IVI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e3.86(1.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e3.73(1.58)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.87\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage initial BCVA,\u003cbr\u003eETDRS letter score, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e55.43(20.92)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e41.4(17.71)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage BCVA improvement,\u003c/p\u003e\n \u003cp\u003eETDRS letter score, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e18.43(16.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e26.47(17.52)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.93\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage initial CRT,\u003cbr\u003e\u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e548.29(231.64)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e516.33(130.41)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.68\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage CRT improvement, \u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e262.43(197.38)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e237.67(135.46)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.27\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003ea: two sample t-test\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2. baseline characteristics and treatment effects among classified groups.\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAbbreviations: BCVA, best-corrected distance visual acuity; CRT, central retina thickness; IVI, intravitreal injection\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"643\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003eCrude association,\u0026nbsp;\u003cbr\u003e\u0026nbsp;p value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003eAdjusted association,\u0026nbsp;\u003cbr\u003e\u0026nbsp;p value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003eImprovement in BCVA\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eInitial BCVA(ETDRS letters)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.08\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; 0.030*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.457\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;0.832\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eTime from symptoms to treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.987\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e0.272\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eDiabetes mellitus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.182\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e0.15\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.505\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e0.448\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003eImprovement in CRT\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eInitial CRT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt;0.001*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt;0.001*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.479\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e0.978\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eTime from symptoms to treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.038*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e0.146\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eDiabetes mellitus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.356\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e0.575\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"36.7601246105919%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.660436137071652%\" valign=\"top\"\u003e\n \u003cp\u003e0.604\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.57943925233645%\" valign=\"top\"\u003e\n \u003cp\u003e0.058\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e*: p value≦0.05\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3.\u003c/strong\u003e Association between clinical factors and improvement in either BCVA or CRT.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAbbreviations: BCVA, Best Corrected Visual Acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"680\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003eGroup 2\u003cbr\u003e\u0026nbsp;(First Bevacizumab and then Ranibizumab or all Ranibizumab)\u003cbr\u003e\u0026nbsp;n=7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003eBRAVO 12 months trial\u003c/p\u003e\n \u003cp\u003eN=131\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP value\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage amount of IVI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e3.86(1.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e8.4(-)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage initial BCVA,\u003cbr\u003eETDRS letter score, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e55.43(20.92)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e53.0(12.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage BCVA improvement,\u003c/p\u003e\n \u003cp\u003eETDRS letter score, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e18.43(16.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e18.3(14.89)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.98\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage initial CRT,\u003cbr\u003e\u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e548.29(231.64)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e551.7(223.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP=0.97\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage CRT improvement, \u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e262.43(197.38)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e347.4(-)\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003ea:\u003csup\u003e\u0026nbsp;\u003c/sup\u003etwo sample t-test\u003c/p\u003e\n \u003cp\u003eb: inadequate information to obtain standard deviation\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4. baseline characteristics and treatment effects between Group 2 and BRAVO 12 months trial.\u003c/strong\u003e Abbreviation: BCVA, best corrected visual acuity; CRT, central retinal thickness; IVI, intravitreal injection\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"680\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003eGroup 3\u003cbr\u003e\u0026nbsp;(First Bevacizumab and then Aflibercept or all Aflibercept)\u003cbr\u003e\u0026nbsp;n=15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003eVIBRANT 52weeks trial\u003c/p\u003e\n \u003cp\u003eN=91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage amount of IVI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e3.73(1.58)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e9.0(1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP\u0026lt;0.0001\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with improvement \u0026lt;15ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e2(13.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e32(35.16%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" rowspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003eP=0.223\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.49488054607509%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with improvement≧15 ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"32.25255972696246%\" valign=\"top\"\u003e\n \u003cp\u003e12(80%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"32.25255972696246%\" valign=\"top\"\u003e\n \u003cp\u003e52(57.14%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.49488054607509%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with ETDRS letters loss(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"32.25255972696246%\" valign=\"top\"\u003e\n \u003cp\u003e1(6.67%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"32.25255972696246%\" valign=\"top\"\u003e\n \u003cp\u003e7(7.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage initial CRT,\u003cbr\u003e\u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e516.33(130.41)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e-\u003csup\u003ec\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003e-\u003csup\u003ec\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.58823529411765%\" valign=\"top\"\u003e\n \u003cp\u003eAverage CRT improvement, \u0026mu;m, mean(SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e237.67(135.46)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.794117647058822%\" valign=\"top\"\u003e\n \u003cp\u003e283.9(-)\u003csup\u003ec\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003e-\u003csup\u003ec\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003ea: two sample t-test\u003c/p\u003e\n \u003cp\u003eb: Fisher\u0026apos;s exact test\u003c/p\u003e\n \u003cp\u003ec: not available data for further calculation\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5.\u003c/strong\u003e baseline characteristics and treatment effects between Group 2 and VIBRANT 52weeks trial. Abbreviation: IVI, intravitreal injection\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"680\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"38.970588235294116%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003eGroup 3\u003cbr\u003e\u0026nbsp;(First Bevacizumab and then Aflibercept or all Aflibercept)\u003cbr\u003e\u0026nbsp;n=15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.205882352941178%\" valign=\"top\"\u003e\n \u003cp\u003eVIBRANT 52weeks trial\u003c/p\u003e\n \u003cp\u003eN=91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"38.970588235294116%\" valign=\"top\"\u003e\n \u003cp\u003eAverage amount of IVI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e3.73(1.58)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.205882352941178%\" valign=\"top\"\u003e\n \u003cp\u003e9.0(1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" valign=\"top\"\u003e\n \u003cp\u003eP\u0026lt;0.0001\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"38.970588235294116%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with improvement \u0026lt;5ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.205882352941178%\" valign=\"top\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.823529411764707%\" rowspan=\"9\" valign=\"top\"\u003e\n \u003cp\u003eP=0.265\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with improvement 5~9ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with improvement 10~14ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with improvement 15~29ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with improvement≧30 ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with ETDRS letters loss \u0026lt;5ETDRS letters (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with ETDRS letters loss 5~9ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with ETDRS letters loss 10~14ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.22184300341297%\" valign=\"top\"\u003e\n \u003cp\u003ePortion of patients with ETDRS letters loss≧15 ETDRS letters(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.01023890784983%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.7679180887372%\" valign=\"top\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003ea: two sample t-test\u003c/p\u003e\n \u003cp\u003eb: Fisher\u0026apos;s exact test\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 6.\u003c/strong\u003e baseline characteristics and treatment effects between Group 2 and VIBRANT 52weeks trial (detailed version). Abbreviation: IVI, intravitreal injection\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Anti-VEGF, anti-vascular endothelial growth factor, BRVO, branch retinal vein occlusion, IVI, intra-vitreal injection","lastPublishedDoi":"10.21203/rs.3.rs-4478566/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4478566/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThis study aimed to investigate the anatomical and functional outcomes of branch vein occlusion (BRVO) eyes treated with anti-VEGF injections using a novel One and Stepped pro re nata (PRN) protocol. This retrospective case series evaluated the electronic medical records from 22 BRVO patients who were treated with anti-VEGF agents under our novel \u0026ldquo;One and Stepped PRN\u0026rdquo; protocol at a single tertiary medical center between January 2016 and October 2022. Outcomes of interest included best-corrected visual acuity and central retinal thickness. 22 treatment-naive BRVO eyes (14 males, eight females) were included. The mean age was 65.82+/- 10.88 years. Average follow-up was 54.45 +/- 7.65 weeks. 7 (31.81%) received mainly Ranibizumab, and 15 (68.18%) received mainly Aflibercept. The baseline average BCVA was 45.86 +/- 19.46 ETDRS letters, and the baseline average CRT was 562.5 +/- 164.02 \u0026micro;m. The mean number of injections received was 3.54 +/- 1.74. Average BCVA improvement was 23.91 +/- 17.36 ETDRS letters (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and average CRT improvement was 245.55 +/- 153.31 \u0026micro;m (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). Our results were comparable to the BRAVO and VIBRANT trials while comparatively using fewer anti-VEGF injections. In summary, our novel anti-VEGF protocol applied under real-world conditions achieved good anatomical and visual outcomes among treatment-naive BRVO eyes.\u003c/p\u003e","manuscriptTitle":"Comparing the effectiveness of treating branch retinal vein occlusion with a novel One and Stepped Pro Re Nata treatment protocol","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-06-12 17:44:25","doi":"10.21203/rs.3.rs-4478566/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"c796e415-0f1d-4e6b-b53a-d10fe7cd685a","owner":[],"postedDate":"June 12th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":33012949,"name":"Health sciences/Health care/Therapeutics/Drug therapy"},{"id":33012950,"name":"Health sciences/Diseases/Eye diseases/Retinal diseases"}],"tags":[],"updatedAt":"2025-09-04T17:50:09+00:00","versionOfRecord":{"articleIdentity":"rs-4478566","link":"https://doi.org/10.1097/MD.0000000000043931","journal":{"identity":"medicine","isVorOnly":true,"title":"Medicine"},"publishedOn":"2025-08-15 00:00:00","publishedOnDateReadable":"August 15th, 2025"},"versionCreatedAt":"2024-06-12 17:44:25","video":"","vorDoi":"10.1097/MD.0000000000043931","vorDoiUrl":"https://doi.org/10.1097/MD.0000000000043931","workflowStages":[]},"version":"v1","identity":"rs-4478566","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4478566","identity":"rs-4478566","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}